Bone Biologics Corp
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, 2023 · Year Ended December 31, 2022 | ||||
|---|---|---|---|---|
| Cash flows from operating activities | ||||
| Net loss | $(8,948,731) | $(1,484,620) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Stock-based compensation | 152,599 | 266,633 | ||
| Finance cost related to public offering | - | 731,714 | ||
| Change in fair value of warrant liability | (892,693) | (2,912,267) | ||
| Changes in operating assets and liabilities: | ||||
| Advances on research and development contract services | 251,066 | (579,910) | ||
| Prepaid expenses and other current assets | (5,335) | (377,015) | ||
| Accounts payable and accrued expenses | 255,876 | 4,877 | ||
| Research and development contract liabilities | (783,675) | 783,675 | ||
| Accrued legal settlement | 414,989 | - | ||
| Net cash used in operating activities | (9,555,904) | (3,566,913) | ||
| Cash flows from financing activities | ||||
| Proceeds from sale of common stock units in public offering, net of offering costs | 5,044,161 | 4,429,860 | ||
| Net cash provided by financing activities | 5,044,161 | 4,429,860 | ||
| Net (decrease) increase in cash | (4,511,743) | 862,947 | ||
| Cash, beginning of year | 7,538,312 | 6,675,365 | ||
| Cash, end of year | $3,026,569 | $7,538,312 | ||
| Supplemental information | ||||
| Interest paid - related party | $ | - | $ | - |
| Income taxes paid | $ | - | $ | - |
| Non-cash financing activities | ||||
| Fair value of warrant liability recognized upon issuance of warrants | $ | - | $5,161,574 | |
| Extinguishment of warrant liability upon exercise of warrants | $711,024 | $589,839 | ||
| Issuance of shares upon cashless exercise of warrants | $11 | $5 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.